A leading proxy advisory firm is recommending that shareholders of Mylan vote against the local generic drug maker’s proposed acquisition of over-the-counter drug specialist Perrigo Co.

Institutional Shareholder Services in Rockville, Md., said it concluded that there were too many uncertainties surrounding the hostile bid.

“What the company has asked shareholders to approve ... is not a compelling acquisition strategy,” ISS wrote in a report released today.

“Approving this proposal requires too heavy a belief that the ‘real’ synergistic opportunity is much greater than Mylan has been able to demonstrate,” and that the acquisition can be completed without Mylan having to raise its offering price of $75 cash and 2.3 Mylan shares, the firm said.

Advertise with us

“The only certainty for Mylan shareholders is that in approving this proposal they would sign up for significant dilution.”

Proxy advisory firms advise pension funds and other institutional investors on how to vote their shares.

Mylan this morning issued a statement saying that ISS “misunderstands and/or underestimates” many key aspects of the transaction.

“We are confident that acquiring Perrigo is the right next strategic step for Mylan and its shareholders,” executive chairman Robert Coury said.

Mylan shareholders will be asked to approve the acquisition of Perrigo at a special meeting in Amsterdam on Aug. 28. Mylan, which has its operations base in Cecil, reincorporated in the Netherlands this year.

Advertise with us

If Mylan gets the nod, it plans to take the merger offer -- which has been rejected by Perrigo’s board -- directly to Perrigo shareholders.

Also today, the investment management firm Paulson & Co. said it voted all of its 21.9 million Mylan shares in favor of the  Perrigo transaction, saying the combination of the two companies would create a “global pharmaceutical powerhouse.” Paulson & Co., which has a 4.5 percent stake in Mylan, is the company’s sixth largest shareholder behind Teva Pharmaceutical Industries.

Earlier this week, two other proxy advisory firms -- Glass Lewis & Co. and Egan-Jones -- recommended that Mylan shareholders approve the Perrigo deal.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.